Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

Latest Posts

About This Stock More About This Stock
Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
Article By: ChinaBio® Today
Saturday, September 24, 2022 2:00 PM EST
Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma sold its 12% stake in its partner for $34 million.
In this article: 1177.HK, 2162.HK, 9995.HK, BLTE, 2315.HK Also: MRK, CASI, IVA
Read
Week In Review: Biocytogen, A Genetically Modified Animal Models Company, Stages $60 Million IPO
Article By: ChinaBio® Today
Saturday, September 3, 2022 3:51 PM EST
Beijing Biocytogen Pharma completed a $60 million IPO on the Hong Kong Exchange for its genetically modified animal and cell model business, which it offers to pharmaceutical/biotech companies. Biocytogen has a market capitalization of $357 million. 
In this article: 2315.HK Also: JNJ, ACOR, IMAB, 300558.SZ, 2257.HK
Read

Latest Tweets for $2315.HK

No tweets yet!

PARTNER HEADLINES